Company intelligence / Profile preview

KMPL

Thailand

Ownership: Private
Development stage: Other

Overview

KMP Biotech is Thailand’s first private company to commercially manufacture probiotics for humans and animals, with a platform emphasizing strain quality, antibiotic resistance gene control, and proven efficacy and safety. There is no clinical trial data typical of biopharma; products are supported by internal scientific research and compliance with international standards (GMP, HACCP, FAMI-QS)[1][3].

Therapeutic areas: Other
Modalities: Live biotherapeutic product therapyProbiotics
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on KMPL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KMPL.

Explore the full profile